Glenmark Pharmaceuticals Inc., USA (Glenmark) has unveiled its new travoprost ophthalmic solution USP, 0.004% (ionic buffered solution), in the American market. This product is considered bioequivalent and therapeutically alike to the benchmark drug, Travatan Z ophthalmic solution USP, 0.004% by Sandoz, Inc.
IQVIA sales data reveal that as of the 12-month period ending September 2024, the market for Travatan Z ophthalmic solution USP, 0.004% amassed approximately $66.2 million in annual sales.
Highlighting the launch, Jim Brown, senior vice president of sales & marketing, stated, “We are thrilled to introduce travoprost ophthalmic solution USP, 0.004% to our growing lineup of prescription eye care products. This launch underscores our dedication to addressing market demand and providing top-tier solutions for our clientele.”
Glenmark’s existing collection features 200 products sanctioned for distribution within the US, alongside 51 ANDAs awaiting approval from the US FDA. Beyond internal filings, Glenmark actively seeks external collaboration opportunities to bolster and expedite the expansion of its current pipeline and product inventory.
Glenmark Pharmaceuticals Ltd. stands as a research-driven, global pharmaceutical entity, with a diverse presence in branded, generic, and OTC segments, concentrating on therapeutic domains such as respiratory, dermatology, and oncology.